Hindsight is easy but PDL1 expression appears to strongly predict pCR. That should help pave the path forward.
nature.com/articles/s4159…

We need to change the paradigm in LA-HNSCC. Adding anti-PD1/PDL1 concurrently or adjuvantly has not worked. I think the solution will come with better biomarkers, changing radiation dosing, and rationally applied therapy sequencing. thelancet.com/journals/lanon…

Intriguing mechansim underscoring the influence of cancer associated fibroblasts in treatment resistence. These cells are not just bystanders.
science.org/doi/10.1126/sc…

Targeting antigens with TCR-T and vaccine simultaneously offers a potential strategy to enhance efficacy of both.
aacrjournals.org/cancerimmunolr…

Impressive clinical responses to CD19 CAR-T in patients with autoimmune disease. 'Immunosuppressive therapy was completely stopped in all the patients.'
nejm.org/doi/full/10.10…

Interesting and thorough analysis of extrachromosomal DNA which appears to correlate with worse outcome in GI cancers treated with anti-PD1 alone but better outcomes with chemo-immotherapy.
nature.com/articles/s4146…

I am delighted to be a part of this comprehensive assessment of irAEs in almost 9000 patients treated on pembrolizumab clinical trials.
ejcancer.com/article/S0959-…

Highlighting the critical role of TME in CAR-T therapy.
nature.com/articles/s4159…

Demonstrating the importance of homologous recombination repair signatures in therapy decisions.
nature.com/articles/s4159…

Two papers published looking at anti-PD1 in kidney transplant patients with skin cancer. Looks like the level and type of immunosuppression is important to protect the organ. Meanwhile, cutaneous SCC appears to still be responsive.
ascopubs.org/doi/10.1200/JC…
ascopubs.org/doi/10.1200/JC…

An interesting example of how to take advantage of an intrinsic feedback loop within cancer cells. cell.com/cancer-cell/fu…

The combination of ADC and immunotherapy is proving to be more than additive. We have to find ways to accelerate development and approval of these combinations. nature.com/articles/s4159…

Thanks to all collaborators on this important publication demonstrating utility of anti-PD1 in a form of oral pre-cancer and potential predictive biomarker of efficacy.
jamanetwork.com/journals/jamao…

Pembrolizumab improved survival in 2nd line R/M HNSCC irrespective of pattern of disease recurrence.
sciencedirect.com/science/articl…

Thanks to CCR for publishing our review on neoadjuvant immunotherapy. The next wave of improved survival with IO.
aacrjournals.org/clincancerres/…

Can thymus radiology predict immune associated myocarditis?
nature.com/articles/s4159…

Pathologic CR is a surrogate of efficacy for neoadjuvant IO. It stands to reason that approaches that increase pCR will improve survival.
nature.com/articles/s4159…

T-cell engager targeting DLL3 in refractory SCLC - impressive early results. nejm.org/doi/full/10.10…

Combinatorial MET and EGFR targeting in EGFR TKI resistant cancers underscores potential activity and importance of longitudinal molecular phenotyping. nature.com/articles/s4159…

Umbrella trial demonstrating the utility of molecular profiling in head and neck cancer. More proof that information is power.
ascopubs.org/doi/full/10.12…